ReviewClinical drug investigation2009
International recommendations for the prevention and treatment of venous thromboembolism associated with cancer.
Review in Clinical drug investigation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine.Clinical and experimental medicine · 2013Review
- Venous thromboembolism in the cancer population: pathology, risk, and prevention.Journal of the advanced practitioner in oncology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism (VTE) is a common complication and a leading cause of death in oncological patients. Recent guidelines have been established for the treatment and prevention of VTE in oncological patients in various clinical situations. These guidelines recommend: (a) prophylactic anticoagulation in all hospitalized oncological patients in whom there are no contraindications; (b) prophylactic anticoagulation in patients scheduled for major oncological surgery in whom there are no contraindications; (c) prolonged (>or=6 months) anticoagulant therapy in oncological patients with manifest VTE in order to prevent a new episode; (d) no routine prophylactic anticoagulation in ambulatory patients without VTE receiving chemotherapy, except when they are receiving treatment with anti-cancer agents with a high risk of thrombogenicity, such as thalidomide- or lenalidomide-based chemotherapeutic regimens; and (e) no use of prophylactic anticoagulants to improve survival in patients with cancer without manifest VTE. Although vitamin K antagonists, unfractionated heparin and in some cases fondaparinux sodium could be used for the treatment of VTE, low molecular weight heparins are recommended for initial and continuous anticoagulant treatment in oncological patients with VTE, as well as for its prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.